PD-L1 anticorps (PE-Cy7)

N° du produit ABIN2659205

Cet anticorps anti-PD-L1 est un anticorps Monoclonal produit chez le Souris, détectant PD-L1 dans FACS. Convient pour Humain.

Aperçu rapide pour PD-L1 anticorps (PE-Cy7) (ABIN2659205)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est conjugé à/à la PE-Cy7

Application: Flow Cytometry (FACS)

Clone: 29E-2A3

Détail du produit anti-PD-L1 anticorps (PE-Cy7)

Réactivité croisée: Chlorocebus aethiops (Green monkey) (Cercopithecus aethiops), Chimpanzé, Marmoset, Squirrel Monkey (Saimiri spec.), Green Monkey (Chlorocebus sabaeus)

Purification: The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: CD274

Sujet: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

Pathways: Cancer Immune Checkpoints